By Rebecca Moore
Bioheart Inc. recently announced a groundbreaking achievement in the field of cardiovascular cell technology. Using a combination of AdipoCell™ and MyoCell®, Bioheart Inc. has been able to advance its capabilities in cell regenerative therapy. The process involves injecting AdipoCell™ (stem cells obtained from adipose), and MyoCell® (stem cells obtained from muscle) into patients suffering from congestive heart failure. The injection of AdipoCell™ is aimed at stimulating new blood vessels to form in the ischemic tissue, and the MyoCell® is used to stimulate new muscle formation. By injecting the treatment with a MyoCath® Catheter into the damaged areas of the heart, the damaged tissue is able to regenerate, and drastically improve the cardiac function and quality of life for the patient.
Read the full article here.
